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Escherichia coli is the primary cause of urinary tract infection (UTI) in the developed world. The major
factors associated with virulence of uropathogenic E. coli (UPEC) are fimbrial adhesins, which mediate specific
attachment to host receptors and trigger innate host responses. Another group of adhesins is represented by
the autotransporter (AT) subgroup of proteins. In this study, we identified a new AT-encoding gene, termed
upaH, present in a 6.5-kb unannotated intergenic region in the genome of the prototypic UPEC strain CFT073.
Cloning and sequencing of the upaH gene from CFT073 revealed an intact 8.535-kb coding region, contrary to
the published genome sequence. The upaH gene was widely distributed among a large collection of UPEC
isolates as well as the E. coli Reference (ECOR) strain collection. Bioinformatic analyses suggest -helix as the
predominant structure in the large N-terminal passenger () domain and a 12-strand -barrel for the
C-terminal -domain of UpaH. We demonstrated that UpaH is expressed at the cell surface of CFT073 and
promotes biofilm formation. In the mouse UTI model, deletion of the upaH gene in CFT073 and in two other
UPEC strains did not significantly affect colonization of the bladder in single-challenge experiments. However,
in competitive colonization experiments, CFT073 significantly outcompeted its upaH isogenic mutant strain in
urine and the bladder.
Urinary tract infections (UTIs) are among the most common
infectious diseases of humans. It is estimated that 40 to 50% of
adult healthy women have experienced at least one UTI epi-
sode in their lifetime, and there is a tendency for these infec-
tions to become chronic due to a high rate of recurrence.
Almost all patients with an indwelling urinary catheter for 30
days or longer develop catheter-associated UTI, which ac-
counts for 40% of all nosocomial infections (13).
Uropathogenic Escherichia coli (UPEC) is the cause of the
majority (80%) of UTIs in humans and one of the most
common sources of Gram-negative bacteremia in hospitalized
patients. The ability of UPEC to colonize the urinary tract and
cause disease involves adhesins (e.g., type 1 and P fimbriae),
toxins (e.g., hemolysin), and iron acquisition systems that uti-
lize siderophores (e.g., enterobactin, salmochelin, and aero-
bactin) (31, 60). Adherence to the urinary tract epithelium
enables bacteria to resist the hydrodynamic forces of urine
flow, to trigger host and bacterial cell signaling pathways, and
to establish infection. Among adhesins, P and type 1 fimbriae
correlate strongly with uropathogenesis and mediate binding
to specific receptors in the urinary tract (7, 39, 47, 54, 62, 63).
Both P and type 1 fimbriae recognize their receptor targets by
virtue of organelle tip-located adhesins, PapG and FimH, re-
spectively (27, 33).
In addition to fimbrial adhesins, a number of autotrans-
porter (AT) proteins associated with virulence have been char-
acterized for UPEC. These include the secreted toxin Sat (17,
18), the phase-variable outer membrane protein antigen 43
(Ag43) (57), and the surface-located trimeric AT protein
UpaG (59). AT proteins are unique in that their sequence is
sufficient to direct their transport across the bacterial mem-
brane system and final routing of a variable passenger ()
domain to the cell surface. AT proteins are generally highly
similar with respect to the structure of the translocation ()
domain that assists the transport of the -domain across the
outer membrane, whereas they differ substantially in their
-domain, which determines the unique functional character-
istics of AT proteins (23, 24). Once at the bacterial surface, the
-domain may be processed and released into the extracellular
surroundings (e.g., Pet and EspP), or it may be cleaved but
remain in contact with the cell surface via noncovalent inter-
actions with the -domain (e.g., Ag43 and AIDA). Thus, AT
proteins have diverse functions, ranging from cell-associated
adhesins to secreted toxins (24).
Ten putative AT-encoding genes have been identified in the
sequenced genome of the prototype UPEC strain CFT073
(45). In this study, we identified and characterized a new AT-
encoding gene from CFT073, which we have named upaH. The
upaH gene was not identified in the original analysis of the
CFT073 genome sequence due to a sequence misassembly
within a highly repetitive region. We show that upaH encodes
a large cell surface-located AT protein that contributes to
biofilm formation and colonization of the mouse urinary tract
in coinfection experiments.
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MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. The strains and plasmids
used in this study are listed in Table 1. E. coli strains used to study the prevalence
of the upaH gene have been described previously (35) or were part of the E. coli
Reference (ECOR) collection (42). Cells were routinely grown at 37°C on solid
or in liquid Luria broth (LB) medium (5) supplemented with the appropriate
antibiotics: kanamycin (Kan) (50 g/ml), ampicillin (Amp) (100 g/ml), or chlor-
amphenicol (Cam) (30 g/ml). For growth under defined conditions, M9 mini-
mal medium supplemented with 0.2% glucose (49) was used as indicated. The
plasmid pUpaH contains the upaH gene from CFT073 and was created by PCR
amplification using the primers 520 (5-CGCGCTCGAGATAATAAGGAATT
ATTATGCAAAGGAAAACTCTATTGTCG) and 521 (5-CGCGCAAGCTT
TTAGAATGTTTTCTTGAAGT), digestion with XhoI-HindIII, and insertion
into XhoI-HindIII-digested pBAD/Myc-HisA. A final modification of the plas-
mid was made by inserting a kanamycin resistance-encoding gene into the
HindIII site. Resistance to kanamycin was required to facilitate transformation
of these plasmids into the flu-negative gfp-positive K-12 strain OS56. In pUpaH,
expression of upaH is under the control of the arabinose-inducible araBAD
promoter (19). Mutants containing deletions in the upaH gene were constructed
by -red-mediated homologous recombination as previously described (9). Prim-
ers with 50-bp homology extensions (718, 5-GCTTACCCTCTGAATGCTCCT
CTGTAGTCGAACAGAACCTGATGCCATGGGTGTAGGCTGGAGCTG
CTTC; and 719, 5-CTGTCCACCGCCGTTTCGCTGCCGCTGTTCATGCTC
AGGTTAAAGTCACCCATATGAATATCCTCCTTAG) were employed to
amplify the kanamycin resistance cassette used to replace upaH. Mutants were
confirmed via PCR and sequencing using the primers 716 (5-GCAAAGGAA
AACTCTATTGTCG) and 717 (5-GGCTGTTGAAACCACCACC). The upaH
promoter insertion mutant (CFT073PcLupaH) was constructed using a strategy
described previously (8, 57) and the following primers: upstream region (587,
5-AGAACATTACTTCTTTGTGC; and 586, 5-GTGAGAATTACTAACTTG
AGCGAATCAAATGCGTCACATAGATATTTAT), downstream region (584,
5-CATTAAAGAGGAGAAAGGTACCGCATGCAAAGGAAAACTCTATT
GTCGGCCT; and 585, 5-TCGGTATAAGTAAAAACTGA), PcL promoter
and kanamycin resistance cassette (588, 5-CTCTGGCAAGCGCCTCGATTA
CTG; and 589, 5-CATCACCTTCACCCTCTCCACTGAC); verification (592,
5-GCTTGAGACCCGTAGCGATC; 591, 5-CTTCCTCGTGCTTTACGGTA
TCG; 593, 5-AGAGAAATAGTCCCGTCAGC; and 590, 5-CAGAGCAGCC
GATTGTCTGTTG) (8, 57). CFT073PcLupaH was confirmed by PCR amplifica-
tion and subsequent DNA sequencing. CFT073cam was constructed by inserting the
chloramphenicol resistance gene cassette from pKD3 at the lacZ locus using primers
with 50-bp homology extensions (1547, 5-TGATCATTAACTATCCGCTGGATG
ACCAGGATGCCATTGCTGTGGAAGCTTAGGGCGAATTGACATTGTG;
and 1606, 5-CCGCGCCAATAACAGAATTATCCCCGATGGTGACGCCTGG
ATTAATAACCCTGGCAGTTCCCTACTCTCG). The mutant was confirmed via
PCR and sequencing with the following primers: upstream region (1551, 5-CCGG
TGTCTCTTATCAGACC; and 1177, 5-TCACCTTCACCCTCTCCACT), down-
stream region (1638, 5-CTGGAGTGAATACCACGACG; and 1635, 5-TCCCG
GTCGTTTATTTCGCG).
DNA manipulations and genetic techniques. DNA techniques were performed
as previously described (49). Isolation of plasmid DNA was carried out using the
QIAprep spin miniprep kit (Qiagen). Restriction endonucleases were used ac-
cording to the manufacturer’s specifications (New England Biolabs). Chromo-
somal DNA purification was made using the GenomicPrep cell and tissue DNA
isolation kit (Amersham Pharmacia Biotech Inc.). Oligonucleotides were pur-
chased from Sigma, Australia. The upaH gene was amplified with the Expand
long-template polymerase system (Roche) as described by the manufacturer.
DNA sequencing was performed using the ABI Big Dye ver3.1 kit (ABI) by the
Australian Genome Research Facility, Brisbane, Australia. Prevalence studies
for the upaH gene used NovaTaq DNA polymerase, as described by the manu-
facturer (Novagen), with the primers 524 (5-AGTGAAGGGGCAAAAAC
CTT) and 525 (5-TGAAACCACCACCATTCTGA). The following program
was used: 94°C for 15 s, 50°C for 15 s, and 72°C for 1 min (25). The orientation
of the type 1 fimbrial switch promoter was assessed as described previously (55).
Sequencing of upaH. In vitro transposon mutagenesis of the upaH gene cloned
into pUpaH was performed with the Epicentre EZ::Tn5KAN-2 transposon
mutagenesis kit as described by the manufacturer. A library of overlapping
transposon mutants was generated by mapping the transposon insertion site
relative to the start site of upaH. A primer targeted to the end of the transposon
was used to sequence into upaH.
RT-PCR. For the detection of upaH mRNA by reverse transcriptase PCR
(RT-PCR), urine from six infected mice was collected just prior to euthanasia,
pooled, and added directly to a two-times volume of RNAprotect (Qiagen).
Total bacterial RNA was isolated and purified using an RNeasy minikit (Qia-
gen). After purification, RNA was treated with RNase-free DNase I (Novagen)
to remove contaminating DNA and repurified using Qiagen RNeasy columns.
RNA samples were quantified spectrophotometrically at 260 nm and additionally
checked by gel electrophoresis. RNA was converted to cDNA using Superscript
III first-strand synthesis supermix as described by the manufacturer (Invitrogen
Life Technologies). cDNA was used directly as a template for PCR using primers
specific for upaH (524 and 525). A negative control using the original RNA was
run in parallel to confirm the absence of contaminating DNA.
Purification of truncated UpaH, antibody production, and immunoblotting. A
747-bp segment from the passenger-encoding domain of upaH was amplified
with the primers UpaHTF (5-GGCCATGGAAATCGCGGGTAATAACGCG
GTGGTGAACCAGGA) and UpaHTR (5-GGAAGCTTGGCAAATATACT
GATGAGTT), digested with NcoI/HindIII, and ligated into NcoI/HindIII-di-
gested pBAD/Myc-HisB. The resultant plasmid (pUpaHTruncated) contained
the base pairs 5050 to 5796 of upaH fused to a 6His-encoding sequence. E. coli
BL21 was transformed with the plasmid pUpaHTruncated, induced with arabi-
nose, and the resultant 6His-tagged protein was purified using the Qiagen
nickel-nitrilotriacetic acid (Ni-NTA) spin kit according to the manufacturer’s
instructions. Protein purity was assessed by SDS-PAGE analysis as previously
TABLE 1. Bacterial strains and plasmids used in this study
Strain or plasmid Relevant characteristic(s) Reference
E. coli strains
BL21 F	 ompT hsdS(rB
	 mB
	) dcm gal Stratagene
CFT073 Wild-type UPEC isolate 38
CFT073cam CFT073lacZ::cam-gfp; Camr This study
CFT073upaH CFT073upaH::kan; Kanr This study
CFT073PcLupaH CFT073PcLupaH; constitutively expressed UpaH This study
M161 Wild-type UPEC isolate This study
M161upaH M161upaH::kan This study
M357 Wild-type UPEC isolate This study
M357upaH M357upaH::kan This study
MS427 MG1655flu 46
OS56 MG1655flu; GFP
; Ampr 53
Plasmids
pUpaHTruncated 747-bp portion of upaH gene from CFT073 was amplified with primers UpaHTF and UpaHTR, digested
with NcoI-HindIII, and ligated into NcoI-HindIII-digested pBAD/Myc-HisB; Ampr
This study
pUpaH upaH gene from CFT073 was amplified with primers 520 and 521, digested with XhoI-HindIII, and
ligated into XhoI-HindIII-digested pBAD/Myc-HisA-kan; Ampr Kanr
This study
pSG10 Chloramphenicol resistance gene from pKD3 inserted into HindIII site of gfp expression plasmid pKEN2 This study
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described (58). Polyclonal anti-UpaH serum was raised in rabbits by the Institute
of Medical and Veterinary Sciences (South Australia), following a standard
protocol (http://www.imvs.sa.gov.au/). For immunoblotting, whole-cell lysates
were subjected to SDS-PAGE using NuPAGE Novex 3 to 8% Tris-acetate
precast gels with NuPAGE Tris-acetate running buffer and subsequently trans-
ferred to polyvinylidene difluoride (PVDF) microporous membrane filters using
the iBlot dry blotting system as described by the manufacturer (Invitrogen).
Serum raised against the passenger subunit of UpaH was used as primary serum,
and the secondary antibody was alkaline phosphatase-conjugated anti-rabbit
IgG. Sigma Fast 5-bromo-4-chloro-3-indolylphosphate–nitroblue tetrazolium
(BCIP/NBT) was used as the substrate in the detection process.
Biofilm assays. Biofilm formation on polystyrene surfaces was monitored by
using 96-well microtiter plates (BD Falcon) essentially as previously described
(52). Briefly, cells were grown for 24 h in glucose M9 minimal medium (con-
taining 0.1% arabinose for induction of upaH gene expression) at 37°C, washed
to remove unbound cells, and stained with crystal violet. Quantification of bound
cells was performed by addition of acetone-ethanol (20:80) and measurement of
the dissolved crystal violet at an optical density of 595 nm. Flow chamber
experiments were performed as previously described (30, 51). Briefly, biofilms
were allowed to form on glass surfaces in a multichannel flow system (4 ml/h)
that permitted online monitoring of community structures. Flow cells were in-
oculated with optical density at 600 nm (OD600)-standardized cultures pregrown
overnight in glucose M9 minimal medium. For E. coli OS56 biofilms, kanamycin
was added as required for maintenance of plasmids. CFT073, CFT073upaH, and
CFT073upaHPcL strains were tagged by introduction of the gfp-containing plas-
mid pSG10, and biofilms were grown as described above but in the presence of
chloramphenicol. Biofilm development was monitored by confocal scanning laser
microscopy at 24 h or 40 h after inoculation. For analysis of the flow cell biofilms,
16 z-stacks were collected for each strain and analyzed by using the COMSTAT
software program (26). All experiments were performed in triplicate.
Microscopy and image analysis. An anti-UpaH specific serum was used for
immunofluorescence microscopy and immunogold electron microscopy as pre-
viously described (56, 59). Microscopic observation of biofilms and image acqui-
sition were performed on a scanning confocal laser microscope (LSM510 Meta;
Zeiss) equipped with detectors and filters for monitoring of green fluorescent
protein (GFP). Vertical cross sections through the biofilms were visualized by
using the Zeiss LSM image examiner. Images were further processed for display
by using Photoshop software (Adobe, Mountain view, CA).
Mouse model of UTI. Female C57BL/6 mice (8 to 10 weeks) were purchased
from the University of Queensland Animal Facility and housed in sterile cages
with ad libitum access to sterile water. The mouse model of UTI described
previously was used for this study (48). Briefly, an inoculum of 20 l, containing
5  108 CFU of bacteria in phosphate-buffered saline (PBS) containing 0.1%
India ink, was instilled directly into the bladder using a 1-ml tuberculin syringe
attached to the catheter. Urine was collected from each mouse at 18 h after
inoculation for quantitative colony counts. Mice were euthanized at 18 h after
challenge by cervical dislocation; bladders and kidneys were then excised asep-
tically, weighed, and homogenized in PBS. Bladder and kidney homogenates
were serially diluted in PBS and plated on LB agar for colony counts. Data are
expressed as the median number of CFU per 0.1 g of bladder tissue or ml of
urine. All animal experiments were repeated at least twice. Competitive mixed-
infection assays were performed as described above except that mice were inoc-
ulated with a mixture of 2.5  108 CFU of CFT073cam and 2.5  108 CFU of
CFT073upaH grown in the absence of antibiotics. The two strains were differ-
entiated by their resistance to chloramphenicol (CFT073cam) and kanamycin
(CFT073upaH), respectively, to enable differential colony counts of the recov-
ered bacteria. Median bacterial CFU were compared using either the nonpara-
metric Mann-Whitney test for the independent challenges or the nonparametric
Wilcoxon matched-pairs test for cochallenge infections within the InStat soft-
ware package (Graphpad, San Diego, CA). P values of 0.05 were considered
significant.
Computational sequence and structure analysis. Amino acid sequence
searches were performed using the BlastP and PSI-BLAST software programs
(1) as implemented on the NCBI (National Center for Biotechnology Informa-
tion) website. Sequence repeats were analyzed using the RADAR (22), REPRO
(16), and XSTREAM (41) software programs. Secondary structure was predicted
using PSI-PRED software program (v2.6) (6). Fold recognition was performed
using the I-TASSER (65) and mGenThreader software (6). The three-dimen-
sional structures were modeled using the program Modeler 9v5 (12). The
BetaWrapPro (37) server was used for the detection of beta-helix motifs. Struc-
ture figures were prepared using the PyMol software program (DeLano Scientific
LLC).
Nucleotide sequence accession number. The complete nucleotide sequence of
upaH has been deposited in the NCBI database (Bankit number 1182914).
RESULTS
Identification of upaH, a new AT-encoding gene in the ge-
nome sequence of UPEC CFT073. We performed a bioinfor-
matic analysis of the E. coli CFT073 genome to search for
novel putative adhesins and identified a 6.5-kb unannotated
intergenic region that contains a disrupted copy of a previously
unidentified AT-encoding gene (Fig. 1A). At the correspond-
ing position on the E. coli K-12 MG1655 genome, there is a
large pseudogene (8622 nucleotides), called ydbA, that has
been truncated by insertion sequences (Fig. 1A). Were it not
for these insertion sequences, ydbA would encode a full-length
AT protein. An intact positional orthologue is also present in
the genome sequence of UPEC strain UTI89, although it has
been misannotated as a major facilitator superfamily-type
transporter (Fig. 1A). In the published genome sequence of E.
coli CFT073, a frameshift is reported in the ydbA gene; how-
ever, this may be a sequencing artifact since there is a section
of uncertainty (CAAGGCGGTYGTSAAYAAA) in this re-
gion. Close examination of the E. coli CFT073 genome sug-
gests that the repeat region of ydbA was misassembled during
genome closure and an intact AT-encoding gene may actually
be present. In accordance with the terminology adopted for
other AT-encoding genes of UPEC (45), we have termed the
ydbA gene upaH. PCR amplification of the entire upaH gene
from E. coli CFT073 revealed a product that was approxi-
mately 2 kb larger than that expected based on the published
genome sequence, confirming an error in genome assembly. In
order to sequence the upaH gene, the upaH PCR product was
cloned as a transcriptional fusion downstream of the tightly
regulated araBAD promoter in the pBAD/Myc-HisA expres-
sion vector to generate the plasmid pUpaH. In vitro transposon
mutagenesis was employed to generate a library of overlapping
transposon mutants, which enabled sequencing across the re-
petitive region of the gene. This revealed that, in contrast to
the published genome sequence, the E. coli CFT073 upaH
gene is an intact coding region of 8.535 kb in length.
Bioinformatic analysis of UpaH predicts it is an AT protein.
Analysis of the translated upaH sequence using the Conserved
Domain Database (CDD) search (36) detected the AT -do-
main (translocation domain) in the C-terminal region of the
protein (Fig. 1B). Sequence searches against the Protein Data
Bank revealed no significant similarities even when searching
with a position-specific scoring matrix (PSSM) based on PSI-
BLAST searches of the nonredundant protein sequences da-
tabase. The known crystal structures of AT -domains include
NalP from Neisseria meningitidis (43) and EspP from E. coli
(3). The similarity of both of these structures with the -do-
main of UpaH could be detected by the fold recognition algo-
rithm I-TASSER (65). Alignment of the UpaH and NalP -do-
main sequences with ClustalW (34) shows 15% identity. We
modeled the structure of this UpaH domain (residues 2528 to
2845) with the software program Modeler (12) using the NalP
structure as a template (Fig. 1C). The model predicts a central
helix (residues 2530 to 2556) winding through a 12-strand
-barrel. The periplasmic -barrel loops are short and well
defined in the model; on the other hand, the extracellular loops
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FIG. 1. (A) Physical map indicating the genomic location of upaH in E. coli CFT073, UTI89, and MG1655. (B) Schematic illustration of the
domain organization of UpaH from E. coli CFT073. Indicated are the signal peptide, the repeat region within the passenger domain, and the
transmembrane -domain. Numbers indicate amino acid positions of region boundaries. (C) Predicted structure of the -domain of UpaH. Shown
is a ribbon diagram of the structure of the -domain (residues 2528 to 2845) obtained by homology modeling based on the crystal structure of the
NalP -domain (43), colored blue (N terminus) through green and yellow to red (C terminus). (D) Amino acid sequence of the repeats present
in UpaH. Amino acids in red indicate 98% conservation; amino acids in blue indicate 55% conservation.
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are longer and show more variability in different models cre-
ated by Modeler, suggesting they are less well defined in the
model (in particular the loops connecting -barrel strands 1
and 2 [residues 2573 to 2579], 3 and 4 [residues 2616 to 2624],
5 and 6 [residues 2673 to 2679], and 9 and 10 [residues 2783 to
2802]). The large passenger domain of UpaH contains 50
imperfect tandem sequence repeats (Fig. 1D). The smallest
repeating unit alternates in length between 24 and 25 amino
acids, and larger-length repeats are evident that are multiples
of 24 to 25 (98, 147, 196, etc). It appears that the sequence of
this domain may have evolved through a number of sequential
duplications involving fragments containing variable numbers
of repeats. The predominant secondary structure predicted in
this domain is -structure, and a repeating pattern of three
-sheets per sequence repeat can be observed.
The upaH gene is highly prevalent among E. coli isolates.
The widespread occurrence of AT-encoding genes in E. coli
prompted us to investigate the prevalence of upaH in UPEC
isolates from our laboratory collection, as well as the 72 strains
from the E. coli reference (ECOR) collection. For this pur-
pose, we employed primers designed to amplify the region
encompassing nucleotides 8083 to 8410 of upaH. We found
that the correct-size base pair product was amplified from
90/118 (76%) of the UPEC strains (15/21 cystitis strains, 28/31
pyelonephritis strains, and 47/66 asymptomatic bacteriuria
[ABU] strains), as well as 65/72 (90%) of the ECOR strains.
The presence of upaH as assessed by PCR was also determined
for these strains according to their phylogenetic group and
revealed the following prevalence pattern: group A, 30/35
(86%); B1, 17/20 (85%); B2, 80/95 (84%); and D, 23/33 (70%).
These results suggest that the upaH gene is widely distributed
among E. coli strains.
The upaH gene encodes a large protein that is located at the
bacterial cell surface. To demonstrate expression of the UpaH
protein, plasmid pUpaH was transformed into the previously de-
scribed E. coli K-12 flu mutant strain MS427 (53). This strain is
unable to mediate the classical cell aggregation and biofilm phe-
notypes associated with Ag43 expression (46). UpaH expression
was detected using a rabbit polyclonal antiserum targeting a re-
gion of UpaH comprising amino acids 1424 to 1673 of the N-
terminal passenger domain. Western blot analysis employing anti-
UpaH antibodies detected the UpaH protein in whole-cell lysates
prepared from E. coli MS427(pUpaH) following induction with
arabinose. The size of the UpaH protein was approximately 460
kDa, significantly larger than its expected molecular mass of 290
kDa (Fig. 2A). Such a disparity in mass has been observed pre-
viously for proteins containing repeated acidic sequences, includ-
ing the AT protein ShdA from Salmonella enterica (29). UpaH is
also highly acidic, containing 376/2,845 (13.2%) acidic amino ac-
ids (glutamate and aspartate). The overexpression of UpaH also
resulted in multiple smaller bands presumed to be breakdown
products (Fig. 2A).
Our bioinformatic analysis suggested that upaH encodes an
AT protein and thus UpaH may localize to the outer mem-
brane. To test this tenet, we performed immunofluorescence
microscopy (Fig. 2B). UpaH antiserum readily reacted with E.
coli MS427(pUpaH) following induction with arabinose during
growth in LB broth, demonstrating that the N-terminal region
of UpaH was effectively translocated to the cell surface. No
reaction was seen with E. coli MS427(pBAD) cells. The surface
FIG. 2. (A) Western blot analysis of UpaH performed using whole-
cell lysates prepared from E. coli MS427(pBAD) and MS427(pUpaH)
grown in the presence of 0.1% arabinose. (B) Phase-contrast and immu-
nofluorescence microscopy employing UpaH-specific antiserum against
cells of E. coli strains MS427(pUpaH) (i) or MS427(pBAD) (ii) grown in
the presence of arabinose. Overnight cultures were fixed and incubated
with anti-UpaH serum followed by incubation with goat anti-rabbit IgG
coupled to Alexa Fluor 488. (C) Immunogold electron microscopy of E.
coli MS427(pUpaH) (i) and MS427(pBAD) (ii) grown in the presence of
arabinose and labeled with anti-UpaH serum followed by protein A-gold
(10 nm) conjugate. Gold particles were observed on the surface of E. coli
MS427(pUpaH) but not MS427(pBAD).
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location of UpaH was confirmed using immunogold labeling
and electron microscopy (Fig. 2C). E. coli MS427(pUpaH)
cells displayed abundant surface labeling with gold particles
following incubation with UpaH antiserum compared to re-
sults for E. coli MS427(pBAD) cells. Thus, the upaH gene is
functional and encodes a large protein located at the cell sur-
face in E. coli.
Phenotypic properties of UpaH. The presence of multiple
repeats within the predicted passenger-encoding domain of
UpaH suggested it may possess some functional properties
similar to those of the well-characterized Ag43 and AIDA-I
AT proteins. However, we saw no evidence of UpaH-mediated
cell aggregation in E. coli MS427 harboring pUpaH (data not
shown). UpaH overexpression also failed to mediate adher-
ence to T24 bladder epithelial cells or to the extracellular
matrix proteins collagen I, collagen III, collagen IV, fibronec-
tin, and laminin (data not shown). To determine whether the
UpaH protein promotes biofilm formation, we examined the
effect of UpaH overexpression in E. coli MS427 (or the gfp-
tagged derivative strain OS56) using static and dynamic biofilm
assays. First, we employed a static nontreated polystyrene mi-
crotiter plate model and showed that UpaH promotes biofilm
formation after growth in M9 minimal medium (Fig. 3A).
Next, we tested the ability of UpaH to promote biofilm forma-
tion under dynamic conditions using the continuous-flow-
chamber model, which permits monitoring of the bacterial
distribution within an evolving biofilm at the single-cell level
due to the combination of GFP-tagged cells and scanning con-
focal laser microscopy. UpaH promoted strong biofilm growth
under these conditions and produced a structure with a depth
of approximately 10 m (Fig. 3B).
The UpaH protein is expressed in UPEC isolates. To deter-
mine whether UpaH is expressed in E. coli CFT073, we con-
structed a upaH deletion mutant employing -red-mediated
homologous recombination of linear DNA (referred to as
CFT073upaH). Examination of whole-cell lysates prepared
from these isogenic strains following growth in LB broth by
SDS-PAGE and Western blotting demonstrated expression of
UpaH in E. coli CFT073 but not in CFT073upaH (Fig. 4A).
Furthermore, complementation of CFT073upaH with plasmid
pUpaH restored the ability of this strain to produce UpaH
(albeit with evidence of protein degradation) (Fig. 4A). We
also randomly selected 16 UPEC strains positive in the upaH
PCR screen and tested them for the ability to express the
UpaH protein following growth in LB by Western blot analysis
employing UpaH-specific antiserum. A band corresponding to
the UpaH protein was identified in all of these strains (data not
shown). To confirm that this was in fact UpaH, we deleted the
upaH gene in two strains (i.e., M161 and M357) using -red-
mediated homologous recombination. Whole-cell lysates pre-
pared from E. coli M161upaH and M357upaH failed to react
with the UpaH-specific antiserum (Fig. 4B). Thus, UpaH is a
newly identified AT protein expressed by E. coli CFT073 and
other UPEC isolates. We also tested for surface localization of
UpaH on E. coli CFT073 using immunofluorescence micros-
copy; however, we could not detect any expression. This was
not caused by a defect in the ability to transport UpaH to the
outer membrane, since surface localization of UpaH was de-
tected in CFT073upaH(pUpaH) and a UpaH overexpression
strain constructed by inserting a chromosomally located con-
stitutive promoter upstream of the upaH coding region
(CFT073PcLupaH) (Fig. 4C).
Deletion of upaH reduces biofilm formation by UPEC strain
CFT073. The contribution of UpaH to biofilm formation by E.
coli CFT073 was assessed, employing both microtiter plate and
flow-cell-based assays. In the microtiter plate assay, E. coli
CFT073 produced a significantly increased biofilm compared
to E. coli CFT073upaH (Fig. 5A). We also examined biofilm
formation by the E. coli M161/M161upaH and M357/
M357upaH isogenic strain sets. E. coli M161 and M357 did not
form a strong biofilm in this assay; there was no significant
difference in the biofilm formed by E. coli M161upaH and
M357upaH (Fig. 5A). To characterize the function of UpaH in
E. coli CFT073 further, we tested the ability of E. coli CFT073,
CFT073upaH, and CFT073PcLupaH to promote biofilm for-
mation in a continuous-flow-chamber system. In this assay,
CFT073upaH formed a biofilm with a lower biovolume, sub-
stratum coverage, and mean thickness than those of the bio-
films formed by E. coli CFT073 and CFT073PcLupaH (P 
FIG. 3. UpaH mediates biofilm formation. (A) Biofilm formation
in polystyrene microtiter plates by E. coli MS427(pBAD) and
MS427(pUpaH) following static growth in the absence (	) or pres-
ence (
) of 0.1% arabinose. Biofilm growth was quantified by
solubilization of crystal violet-stained cells with ethanol-acetone and
determination of the absorbance at 595 nm. Results represent averages
of a minimum of 8 replicates  SEM. Significant biofilm growth was
observed for E. coli MS427(pUpaH) following induction of UpaH
expression with arabinose (*, P  0.001 as determined by analysis of
variance [NOVA]). (B) Dynamic-flow-chamber assay examining bio-
film formation of E. coli OS56(pBAD) and OS56(pUpaH) grown in
the presence of 0.1% arabinose. Biofilm development was monitored
by confocal scanning laser microscopy after 24 h. The images are
representative horizontal sections collected within each biofilm and
vertical sections (to the right of and below each larger panel, repre-
senting the yz plane and the xz plane, respectively) at the positions
indicated by the white lines. E. coli MS427(pUpaH) produced a sig-
nificant biofilm in this assay.
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0.008, P  0.008, and P  0.012, respectively) (Fig. 5B and C).
Taken together, these results demonstrate that UpaH contrib-
utes to biofilm formation by CFT073.
The upaH gene does not contribute to colonization of the
mouse bladder in single-infection experiments. To study the
role of UpaH in virulence, we examined the ability of CFT073
and CFT073upaH to survive in the mouse urinary tract. There
was no significant difference in the number of CFT073 or
CFT073upaH cells recovered from the bladders and urine of
mice following infection (data not shown). No significant col-
onization of the kidneys was observed for either strain; this is
consistent with previous data from our laboratory using
C57BL/6 mice (57, 59). To examine if this was a strain-specific
effect, we also compared E. coli M161/M161upaH and M357/
M357upaH for their ability to colonize the mouse urinary tract
as described above. There was no significant difference in col-
onization of the bladder or recovery from urine for the parent
and upaH mutant of both isogenic strain sets (data not shown);
no significant colonization of the kidneys was observed for any
of the strains.
The upaH gene is expressed during colonization of the
mouse urinary tract. The above result prompted us to examine
whether upaH is transcribed during infection of C57BL/6 mice
by CFT073 using RT-PCR. RNA was extracted from pooled
mouse urine collected 18 h postinoculation and converted to
cDNA. A PCR using upaH-specific primers revealed the pres-
ence of an amplification product from the cDNA samples,
while no PCR product was obtained from the RNA sample
prior to cDNA synthesis (Fig. 6A). Thus, the upaH gene lo-
cated on the E. coli CFT073 chromosome is transcribed during
colonization of the mouse urinary tract.
Deletion of upaH from CFT073 reduces colonization of the
mouse bladder in a mixed-infection experiment. For a more
sensitive method to test the role of upaH in colonization of the
mouse urinary tract, we performed competitive-colonization
experiments where we coinoculated mice with the CFT073 and
FIG. 4. (A) Western blot analysis of UpaH performed using whole-cell lysates prepared from E. coli CFT073, CFT073upaH,
CFT073upaH(pBAD), and CFT073upaH(pUpaH). A band corresponding to UpaH was detected in E. coli CFT073 and CFT073upaH(pUpaH) but
not in E. coli CFT073upaH and CFT073upaH(pBAD). (B) Western blot analysis of UpaH performed using whole-cell lysates prepared from E.
coli M161, M161upaH, M357, and M357upaH. A band corresponding to UpaH was detected in E. coli M161 and M357 but not in E. coli M161upaH
or M357upaH. (C) Phase-contrast (i) or immunofluorescence (ii) microscopy employing UpaH-specific antiserum against cells of E. coli CFT073,
CFT073upaH, CFT073upaH(pUpaH), or CFT073PcLupaH. Overnight cultures were fixed and incubated with anti-UpaH serum, followed by
incubation with goat anti-rabbit IgG coupled to Alexa Fluor 488. A positive reaction indicating surface localization of UpaH was detected only for
CFT073upaH(pUpaH) and CFT073PcLupaH.
VOL. 78, 2010 CHARACTERIZATION OF THE UpaH AT PROTEIN FROM UPEC 1665
CFT073upaH strains in a 1:1 ratio. These experiments were
performed using a derivative of CFT073 tagged at the lacZ
locus with a chloramphenicol resistance gene cassette (i.e.,
CFT073cam) and CFT073upaH (which contains a kanamycin
resistance gene cassette in upaH). The two strains had an
identical growth rate in pooled human urine (and LB broth)
and did not display any difference with respect to type 1 fimbria
production (as assessed by yeast cell agglutination and a fim
switch orientation PCR), hemolysis of red blood cells, and
motility (data not shown). We found that CFT073cam signifi-
cantly outcompeted CFT073upaH at 18 h in urine (P  0.001)
and the bladder (P  0.001) (Fig. 6B). In contrast, we did not
observe a significant difference in colonization using mixed-
infection experiments employing M161/M161upaH or M357/
M357upaH (data not shown). These results suggest that the
ability to express UpaH confers a competitive advantage for
the survival of CFT073 in the mouse urinary tract but that this
effect is not specific to all strains of UPEC.
DISCUSSION
UPEC produces a range of fimbrial and nonfimbrial ad-
hesins that play a role in virulence and contribute to persistent
infection of the urinary tract. Some UPEC fimbrial adhesins,
including type 1 and P fimbriae, have been well characterized
with respect to their expression, regulation, receptor-binding
target, and role in virulence. Of the nonfimbrial adhesins, the
AT family of proteins represents a novel group of virulence
factors because of their role in adhesion, invasion, and biofilm
formation in other organisms. Although UPEC strains possess
multiple AT-encoding genes, very little is known about their
function, and only Ag43, UpaG, and Sat have been shown to
FIG. 5. (A) Biofilm formation in polystyrene microtiter plates by three sets of isogenic strains with respect to upaH: E. coli CFT073 and
CFT073upaH; E. coli M161 and M161upaH; and E. coli M357 and M357upaH. Results represent averages of OD595 readings of at least 4
independent experiments  SEM. There was no difference in the growth of wild-type and upaH mutant strains. (B) Dynamic-flow-chamber assay
examining biofilm formation of E. coli CFT073 (i), E. coli CFT073upaH (ii), and E. coli CFT073PcLupaH (iii). Biofilm development was monitored
by confocal scanning laser microscopy after 40 h. The images are representative horizontal sections collected within each biofilm and vertical
sections (to the right of and below each larger panel, representing the yz plane and the xz plane, respectively) at the positions indicated by the white
lines. (C) Three-dimensional image demonstrating the structure of the biofilm formed by E. coli CFT073 (i), E. coli CFT073upaH (ii), and E. coli
CFT073PcLupaH (iii).
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play a role in virulence. Here we identify and characterize
UpaH as a new AT protein of UPEC and demonstrate that it
contributes to biofilm formation and colonization of the mouse
bladder in a mixed-infection assay.
The upaH gene is not annotated in the genome sequence of
E. coli CFT073 due to a misassembly within a region of highly
repetitive DNA. In E. coli K-12, a large pseudogene (8,622 bp),
called ydbA, that has been truncated by insertion sequences is
located at the corresponding position on the chromosome.
Positional orthologues of ydbA are also discernible in several
other pathogenic and nonpathogenic E. coli strains, although
they are not always intact (e.g., E. coli O157:H7 EDL933
z2322/z2323 represent a split-gene version of ydbA). In the
UPEC strain UTI89 genome, ydbA has been misannotated as
encoding the “EntS/YbdA major facilitator superfamily (MFS)
transporter.” This unfortunate error likely arose because the
EntS MFS enterobactin transporter described by Furrer et al.
(14) was encoded by the gene ybdA. Similarity searches with
the true EntS sequence (gi2506613) clearly demonstrate that
the UTI89 EntS protein and the original EntS/YbdA protein
are not related proteins. The combination of events that led to
the misannotation of upaH emphasizes the need for caution
when assembling highly repetitive regions of genome sequence
data, especially since in some cases these repeats may occur
within genes that encode cell surface proteins. The “genome
rot” caused by the UTI89 EntS error (already propagated to
three recent E. coli genome annotations) also highlights the
need for caution when predicting function based on annotation
alone, even when the annotation has been manually curated.
The passenger domain of UpaH contains 50 imperfect repeats,
each of which comprises 24 to 25 amino acid residues. The solved
structures of passenger domains from other AT proteins, includ-
ing pertactin from Bordetella pertussis (10), hemoglobin protease
from E. coli (44), and pore-forming toxin from Helicobacter pylori
(15), all contain the -helix motif. The -helix structure contains
a superhelical arrangement of structural repeats, each consisting
of three -strands in a triangular arrangement (64). These repeats
pack into a cylindrical solenoid structure, with the -strands form-
ing parallel -sheets along the cylinder. The repeating sequence
pattern in the UpaH passenger domain is consistent with struc-
tural repeats found in a -helix. Despite the lack of detectable
sequence similarities, we therefore propose that the bulk of the
passenger domain would correspond to a -helix structure. Sev-
eral other pieces of evidence support this prediction: (i) the pro-
gram BetaWrapPro (37), which specializes in identifying -helix
motifs, identifies several such motifs in UpaH; (ii) the fold rec-
ognition programs, such as I-TASSER (65) and mGenThreader
(6), suggest the sequence of the UpaH passenger domain is most
compatible with the structures of AT passenger domains and
other -helix proteins; and (iii) most AT passenger domains have
been suggested previously to contain the -helix structure, pre-
sumably to facilitate efficient secretion across the outer mem-
brane and subsequent folding and to present the functional de-
terminant at a distance from the bacterial surface (28).
Short repeat sequences have been described within the pas-
senger domain of two other surface-located AT proteins from
E. coli, namely, AIDA-I (4) and Ag43 (25). AIDA-I contains
21 repeats built up of 19 to 20 amino acid residues followed,
after a short interruption, by an additional 10 repeats. The
repeat structure of Ag43 is less well defined and more variable
in length (12 to 20 amino acids). Repeat sequences often form
solenoid structures with frequent roles in protein-protein in-
teractions (32) and possibly ligand binding (61), both of which
are consistent with the surface location of UpaH (and AIDA-I
and Ag43) and the ability of these proteins to mediate biofilm
formation. Other possible functions of short repeat sequences
FIG. 6. (A) RT-PCR analysis of upaH transcription by CFT073
during colonization of the mouse urinary tract. Urine from six mice
infected with CFT073 was collected and pooled at 18 h postinoculation
and added directly into a 2 volume of RNAprotect (Qiagen).
CFT073 cells were concentrated by centrifugation, and total RNA was
extracted. Lane 1, upaH-specific PCR product (328 bp) obtained from
genomic DNA (positive control); lane 2, 1-Kb Plus DNA ladder (In-
vitrogen); lane 3, PCR employing RNA prior to cDNA synthesis as a
template (negative control); lane 4, upaH-specific PCR product (328
bp) obtained using the cDNA as the template. (B) Competitive mixed-
infection experiment. C57BL/6 mice (n  24) were challenged with a
1:1 mixture of E. coli CFT073cam and CFT073upaH. Total CFU were
enumerated on selective medium to differentiate between CFT073cam
(chloramphenicol resistant) and CFT073upaH (kanamycin resistant).
Each symbol represents the total number of CFU for an individual
mouse per 0.1 g of bladder tissue or the total number of CFU per ml
urine. Lines connect values for the same mouse. Horizontal bars rep-
resent the median values. No significant colonization of the kidneys
was observed.
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may be to increase flexibility, alter the length, incorporate
repetitive domain architecture, and mediate antigenic varia-
tion via duplication or deletion. The precise biological role of
these short repeat sequences in UpaH and their level of con-
servation in UPEC remain to be determined.
In the murine UTI model, UPEC colonization of the blad-
der is associated with the formation of intracellular bacterial
communities (IBCs) within superficial umbrella cells (2). IBCs
possess biofilm-like properties and are comprised of compact
cell clusters encased in a polysaccharide matrix. IBC formation
creates a quiescent state that may be associated with long-term
persistence in the bladder (11, 40). Two cell surface factors
associated with biofilm formation, type 1 fimbriae, and Ag43
are expressed by cells within IBCs (2). We observed a signifi-
cant difference in biofilm formation between CFT073 and
CFT073upaH. However, this difference did not translate into a
significant role for UpaH in the mouse urinary tract in single-
infection experiments. To investigate this further, we also con-
structed a upaH deletion in two other clinical isolates from our
laboratory collection that expressed UpaH (i.e., M161 and
M357). There was no significant difference in bladder coloni-
zation or biofilm growth for M161/M161upaH or M357/
M357upaH. Despite these results, we did observe a competi-
tive advantage for CFT073 for colonization of the urinary tract
in mixed-infection experiments with CFT073upaH. It is possi-
ble that UpaH and other AT proteins (e.g., Ag43 and UpaG)
possess a high degree of functional redundancy with respect to
the biofilm phenotype. The apparent strain-specific effect of
UpaH in CFT073 versus M161/M357 may be associated with
their different biofilm formation properties. Other surface fac-
tors differentially expressed between CFT073, M161, and
M357 (e.g., fimbriae, flagella, and capsule) could also interfere
with the function of UpaH, as has been reported previously for
Ag43 (21, 50, 58). Thus, our in vivo analysis of the function of
UpaH suggests it may play a modulatory role in colonization of
the mouse urinary tract by CFT073 and that this contribution
could occur in concert with other AT proteins (e.g., Ag43 and
UpaG) that possess similar biofilm formation properties.
In a recent study, Hagan and Mobley identified 23 outer
membrane proteins from E. coli CFT073 that elicit a humoral
response in the mouse UTI model (20). This included porins,
transporters, and receptors (including siderophore receptors).
There are several possible reasons for the failure to detect
UpaH in this screen. First, it is possible that as a result of its
very large size, the UpaH protein did not migrate properly into
the gel. We note that despite an apparent molecular mass of
290 kDa, UpaH migrated at approximately 460 kDa. Second,
UpaH may be expressed in vivo at low levels. Although we
were able to detect the presence of a upaH transcript by RT-
PCR, the exact level of UpaH expression in vivo remains to be
determined. Finally, it is possible that UpaH does not elicit a
strong humoral response. However, the highly repetitive se-
quence of the passenger domain and its similarity to other AT
proteins would suggest otherwise. The UpaH homologues
present in the published genomes exhibit some variation in
size, which may reflect the natural variation in the number of
repeats. Alternatively, these genomes may contain incorrect
assemblies due to the challenges of sequencing repetitive re-
gions.
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